| | SEPTEMBER 20254 Editorial Business Leadership ChroniclesVol 4 · Issue 01- 09 · SEPTEMBER, 2025Publisher Alok ChaturvediManaging Editor Sujith Vasudevan GM - Media & Graphic Designing VisualizerPrabhu Dutta A.R.N RayNoidaRohit Raghubanshi Akshay Shettyadvertise@ceoinsightsasia.comEditorial queries editor@ceoinsightsasia.comTo subscribeVisit www.ceoinsightsasia.com/subscribe/ or send emailto subscription@ceoinsightsasia.comMagazine Price is $50 per issuePublisher Alok ChaturvediPrinted and Published By Alok Chaturvedi on behalf of InfoConnect Web Technologies India Pvt. Ltd., and Printed at Executive Prints - 113/7, Ground floor, Old madras road, Halasuru, Bangalore - 560008 and Published At No. 124, 2nd Floor, Surya Chambers, Old Airport Road, Murugeshpalya, Bangalore-560017.Copyright © 2025 InfoConnect Web Technologies India Pvt. Ltd., All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher.Designers Girisha M Rutika MohantyVP - Sales & Marketing Amrit Kumar Singh Circulation Manager Magendran PerumalEditorialViswanathan A Keerthana KantharajLakshmi Prabha S Roopalatha H Meriya SabuIt's no secret that Malaysia is a major global exporter of pharmaceuticals. Last year, the country exported $471 million worth of pharma products, encompassing both generic and over-the-counter medicines. Malaysia exported approximately $109.33 million worth of pharmaceutical products to the United States alone in 2024, making up about 18% of the nation's global pharma exports. Despite the US imposing a general 19 percent tariff on Malaysian goods in August 2025, pharmaceutical exports remain completely exempt, thanks to ongoing bilateral negotiations between both countries. This is not just a great omen for the country, but also a significant business opportunity, which should be driven by technology. It's no coincidence that the country's pharmaceutical industry is projected to generate nearly $1.74 billion in revenue this year.Well, the signs in this regard look promising. Technology is increasingly penetrating the Malaysian pharmaceutical industry through several key advancements in digital transformation, AI, automation, and regulatory innovation. AI is significantly enhancing drug discovery, personalized medicine, and clinical trial efficiency, while automation optimizes manufacturing processes, supply chains, and distribution networks. Let's look at some numbers. Digital transformation in the sector is expected to boost the sector's productivity by over 20 percent by 2027. AI deployment in drug discovery and manufacturing has increased by 35 percent year-on-year, improving efficiency and reducing time-to-market for new medicines. Production and supply chain process automation is projected to reduce operational costs by up to 25 percent within the next three years. These are definitely interesting times to be in the pharma industry. We are delighted to focus the spotlight on some of the leaders from Malaysia's pharma industry. Do let us know your thoughts.Sujith VasudevanManaging Editoreditor@ceoinsightsasia.comMalaysia's Pharma Industry is Taking OffUnlocking the Art andScience of StrategicMarketing BrandDevelopment andManagementDigital MarketingServicesSocial MediaManagementMarketingStrategyDevelopmentCustomerJourney Mappingand ExperienceDesignMarketingCampaignManagement MarketResearch andAnalysis Content Creationand MarketingSales Enablementand SupportMarketingPerformanceMeasurement andReportingEmpower Y o u r B u s i n e s s w i t h V y u g h ' s ServicesMARKETING PARTNERYOURFOR MOREINFORMATIONSTRATEGICSTRATEGICwww.vyughmarketing.comVYUGH MARKETING @vyugh.marketingconnect@vyughmarketing.com
< Page 3 | Page 5 >